155 related articles for article (PubMed ID: 22968854)
1. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.
Inoue Y; Usui N; Hiroki T; Shimizu K; Kobayashi S; Shimasaki S
Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):139-48. PubMed ID: 22968854
[TBL] [Abstract][Full Text] [Related]
2. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
Fischer JH; Patel TV; Fischer PA
Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.
Tanaka J; Kasai H; Shimizu K; Shimasaki S; Kumagai Y
Eur J Clin Pharmacol; 2013 Mar; 69(3):489-97. PubMed ID: 22918614
[TBL] [Abstract][Full Text] [Related]
4. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
[TBL] [Abstract][Full Text] [Related]
5. Safety of fosphenytoin sodium.
Fierro LS; Savulich DH; Benezra DA
Am J Health Syst Pharm; 1996 Nov; 53(22):2707-12. PubMed ID: 8931812
[TBL] [Abstract][Full Text] [Related]
6. Fosphenytoin: a novel phenytoin prodrug.
Boucher BA
Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit.
Muchohi SN; Kokwaro GO; Maitho TE; Munenge RW; Watkins WM; Edwards G
Eur J Drug Metab Pharmacokinet; 2002; 27(2):83-9. PubMed ID: 12064376
[TBL] [Abstract][Full Text] [Related]
8. Fosphenytoin (Cerebyx).
Browne TR
Clin Neuropharmacol; 1997 Feb; 20(1):1-12. PubMed ID: 9037568
[TBL] [Abstract][Full Text] [Related]
9. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin.
Jamerson BD; Dukes GE; Brouwer KL; Donn KH; Messenheimer JA; Powell JR
Pharmacotherapy; 1994; 14(1):47-52. PubMed ID: 8159601
[TBL] [Abstract][Full Text] [Related]
10. Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study.
Ohno Y; Niwa T; Hirai K; Suzuki K; Yamada Y; Hayashi Y; Hayashi H; Suzuki A; Itoh Y
Ther Drug Monit; 2018 Aug; 40(4):507-511. PubMed ID: 29683874
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
Knapp LE; Kugler AR
J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.
Ogutu BR; Newton CR; Muchohi SN; Otieno GO; Edwards G; Watkins WM; Kokwaro GO
Br J Clin Pharmacol; 2003 Jul; 56(1):112-9. PubMed ID: 12848783
[TBL] [Abstract][Full Text] [Related]
13. Effect of therapeutic plasma exchange on phenytoin plasma concentration in patients receiving intravenous fosphenytoin therapy.
Nishida S; Hayashi Y; Hirai K; Takekoshi A; Yamada Y; Kobayashi R; Shimizu S; Niwa T; Hayashi H; Shimohata T; Sugiyama T; Suzuki A
Pharmazie; 2020 Oct; 75(10):488-490. PubMed ID: 33305722
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery.
Wilder BJ; Campbell K; Ramsay RE; Garnett WR; Pellock JM; Henkin SA; Kugler AR
Arch Neurol; 1996 Aug; 53(8):764-8. PubMed ID: 8759983
[TBL] [Abstract][Full Text] [Related]
15. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin.
Löscher W; Reissmüller E; Ebert U
Epilepsy Res; 1998 Mar; 30(1):69-76. PubMed ID: 9551846
[TBL] [Abstract][Full Text] [Related]
16. Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers.
Kaucher KA; Acquisto NM; Rao GG; Kaufman DC; Huntress JD; Forrest A; Haas CE
Pharmacotherapy; 2015 May; 35(5):482-8. PubMed ID: 26011141
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and pharmacokinetics of fosphenytoin.
Browne TR; Kugler AR; Eldon MA
Neurology; 1996 Jun; 46(6 Suppl 1):S3-7. PubMed ID: 8649612
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteers.
Li X; Wu M; Sun J; Jin W; Han L; Xu J; Liu J; Zhang H; Wang J; Wang D; Zhang H; Zhang Q; Liu N; Ding Y
Front Pharmacol; 2023; 14():1204075. PubMed ID: 38044946
[No Abstract] [Full Text] [Related]
19. Safety, Tolerability, and Pharmacokinetics of Fosphenytoin Loading in Patients With Subarachnoid Hemorrhage.
Kim DW; Kim TE; Ji M; Chun YI
Clin Neuropharmacol; 2015; 38(6):248-51. PubMed ID: 26536021
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients.
Higuchi K; Yamashita D; Kashihara Y; Kakara M; Hirota T; Hirakawa M; Ieiri I
Ther Drug Monit; 2019 Oct; 41(5):674-680. PubMed ID: 31095070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
